Immunotherapy boost before surgery shows promise against head and neck cancer
NCT ID NCT05522985
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 5 times
Summary
This study tests whether adding an immunotherapy drug (treprizumab) to standard chemotherapy before surgery can improve outcomes for people with advanced head and neck cancer. About 122 participants will be randomly assigned to receive either the drug combo or chemo alone for three cycles before surgery. The main goal is to see if the combo leads to a higher rate of complete tumor disappearance after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?